Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.


CSE:HUGE - Post by User

Post by JensLenson Jun 14, 2022 11:21am
205 Views
Post# 34755132

New podcast with Dr Kotra talking

New podcast with Dr Kotra talkingYour Complex Brain: Psychedelics and the Mental Health Revolution on Apple Podcasts

More than 50 years after emerging as a potential treatment for anxiety and depression, addiction, post-traumatic stress disorder and other chronic illnesses, psychedelics appear to be making a comeback. But where does the research stand currently on psychedelics and what do we really know about how these compounds may affect the brain?


With the number of people living with mental health conditions on the rise and the re-emergence of psychedelics as a possible therapy, this topic is very timely. Some may call it a “perfect storm” – one the medical and scientific communities will need to carefully navigate, in order to tap the potential of psychedelics, safely and cautiously.


Featuring:

Dr. Susan Abbey is Psychiatrist-in-Chief at the University Health Network (UHN), and a Clinician Investigator with the Toronto General Hospital Research Institute.  She is also a Professor in the Department of Psychiatry at The University of Toronto and the inaugural Director of the Nikean Psychedelic Psychotherapy Research Centre at UHN.


Dr. Lakshmi Kotra is a Medicinal Chemist and Senior Scientist with Krembil Brain Institute and a Professor of Medicinal Chemistry at The University of Toronto. He is also an academic entrepreneur with three decades of expertise in drug discovery, development, and pharmaceuticals, and the co-founder and CEO of Lucid Psycheceuticals.


Additional Resources:

Nikean Psychedelic Psychotherapy Research Centre at UHN

First-of-its-kind research centre will bring psychedelic psychotherapy to UHN

The Revival of Psychedelic Research – ORT Times article

Lucid Psycheceuticals

<< Previous
Bullboard Posts
Next >>